(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of 40.58% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Sarepta Therapeutics's revenue in 2024 is $1,243,336,000.On average, 8 Wall Street analysts forecast SRPT's revenue for 2024 to be $170,323,354,454, with the lowest SRPT revenue forecast at $142,183,437,717, and the highest SRPT revenue forecast at $222,437,321,700. On average, 8 Wall Street analysts forecast SRPT's revenue for 2025 to be $258,264,747,359, with the lowest SRPT revenue forecast at $156,577,103,395, and the highest SRPT revenue forecast at $397,411,024,009.
In 2026, SRPT is forecast to generate $317,179,853,035 in revenue, with the lowest revenue forecast at $180,333,784,774 and the highest revenue forecast at $453,102,008,641.